• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BD, JDRF ink deal for extended-wear insulin delivery device

November 10, 2016 By Sarah Faulkner

BD, JDRF ink deal for extended wear insulin delivery deviceBecton Dickinson (NYSE:BDX) said today that it inked a research collaboration supported by the Juvenile Diabetes Research Foundation to develop an extended-wear insulin delivery device.

The collaboration is a 2-year funding commitment from JDRF to extend the lifetime of insulin infusion-delivery devices. Insulin infusion sets are cleared by the FDA for up to 3 days of use. JDRF will support Franklin Lakes, N.J.-based BD in addressing the mechanical-material and biological issues that contribute to the limited lifetime and design devices that enable infusion sets to be effective for an extended period of time.

“Insulin infusion therapy has substantial clinical benefits for Type I diabetes management, yet its potential is limited by an abbreviated 3-day infusion set usage life,” diabetes care president Ken Miller said in prepared remarks. “Thanks to our latest partnership with JDRF, we can continue to build on the successful innovations BD currently offers in the insulin infusion category. We are extremely excited for this opportunity to advance the science and understanding of insulin delivery.”

“JDRF is pleased to continue our partnership with BD to further reduce the burden of managing infusion sets for people with type 1 diabetes,” added JDRF director of research business development Vincent Crabtree. “Living with diabetes is challenging, and JDRF’s goal is to provide broad access to innovative therapies, ensuring each person with this disease has access to treatments to enable them to have better outcomes and to lead healthy lives.”

The deal comes a week after BD posted fiscal 4th-quarter and full-year results that met or beat the consensus forecast on Wall Street. Notably, the medical product giant’s full-year profits soared 40.4% to $976 million, or $4.49 per share, on sales of $12.48 billion, for a top-line gain of 21.4% compared with fiscal 2014.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Research & Development Tagged With: Becton Dickinson, Juvenile Diabetes Research Foundation (JDRF)

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS